Lung cancer diagnosis marker combination and application

A lung cancer diagnosis and marker technology, applied in the fields of chemical analysis and clinical medicine, can solve the problems of inability to detect lung cancer patients in time, sensitivity and specificity issues, etc.

Active Publication Date: 2019-06-28
上海市生物医药技术研究院
View PDF4 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Existing tumor markers such as neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), cancer antigen-125 (CA125), gastrin-releasing peptide precursor (ProGRP), squamous cell carcinoma antigen (SCCA), tissue polypeptide antigen (TPA), etc. have certain discriminative value in clinical auxiliary diagnosis, curative effect evaluation, prognosis judgment and recurrence monitoring of lung cancer, but the above markers are used alone or in combination There are problems with sensitivity and specificity, and it is impossible to detect early asymptomatic lung cancer patients in time.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lung cancer diagnosis marker combination and application
  • Lung cancer diagnosis marker combination and application
  • Lung cancer diagnosis marker combination and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0045] Below in conjunction with specific embodiment, further illustrate the present invention. For the experimental methods without specific conditions indicated in the following examples, the conventional conditions or the conditions suggested by the manufacturer are usually followed. Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art. In addition, any methods and materials similar or equivalent to those described can be applied to the method of the present invention. The preferred implementation methods and materials described herein are for demonstration purposes only.

[0046] It should be noted that, in the case of no conflict, the embodiments of the present invention and the features in the embodiments can be combined with each other.

[0047] Embodiments of the present invention will be specifically explained below in conjunction with the accompanying drawings. E...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to view more

Abstract

The invention discloses a diagnosis marker combination suitable for early screening and diagnosis of lung cancer. The diagnosis marker combination comprises one of 14 serum (or plasma) metabolites ormore: Acylcarnitine C8, decenoyl-carnitine (Acylcarnitine C10: 1), decanoyl-carnitine (Acylcarnitine C10), lauryl-carnitine (Acylcarnitine C12), dimyristoyl-carnitine (Acylcarnitine C14: 2); lysophosphatidyl-ethanolamine (16: 0) (LPE(16: 0)), lysophosphatidyl-ethanolamine (20: 4) (LPE (20: 4)), lysophosphatidyl-ethanolamine (20: 3) (LPE (20:3)), lysophosphatidyl-choline (20: 3/0: 0) (LPC (20: 3/0:0)), lysophosphatidyl-choline (0: 0/22: 5) (LPC (0: 0/22: 5)); 3-hydroxyl lauroleic acid (FA(12: 1(OH))), 3-hydroxy myristic dienoic acid (FA(14: 2(OH))), 3-hydroxyl linoleic acid (FA (18: (OH))), 3-hydroxy oleic acid (FA (18: 1(OH))). The diagnosis marker can be used for constructing a diagnosis model, and the model is high in sensitivity and good in specificity, can be used for early screeningand diagnosis of lung cancer, and has good clinical use and popularization values.

Description

technical field [0001] The invention relates to the fields of chemical analysis and clinical medicine. It specifically relates to a lung cancer diagnostic marker, a diagnostic model constructed with the diagnostic marker and its application in lung cancer screening and diagnosis. Background technique [0002] Lung cancer is a major disease that seriously endangers human life and health, and its morbidity and mortality rank first among malignant tumors. Because patients with early lung cancer often have no special symptoms, most of the lung cancer patients who are clinically diagnosed are in the middle and late stages, and their 5-year survival rate is only 10-15%. The 5-year survival rate of patients with early-stage lung cancer after surgical resection can reach more than 70%, and the 5-year survival rate of stage I lung cancer is as high as 92%. However, there is still a lack of effective and reliable methods for early screening and diagnosis of high-risk groups of lung ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N30/00
Inventor 吴谦
Owner 上海市生物医药技术研究院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap